Philip Morris Gains FDA Nod for Fast-Growing Nicotine Pouches

Philip Morris International has received authorization from the U.S. Food and Drug Administration (FDA) for 11 of its nicotine pouch products. This regulatory approval significantly bolsters the company's position within the rapidly expanding nicotine pouch market in the United States.

The newly authorized products include the higher-strength Zyn Ultra pouches, which Philip Morris launched in June with pricing below its main Zyn brand. This strategy aims to capture a broader consumer base and solidify market share, although it may present a balance between sales growth and profitability due to lower prices and increased marketing.

The FDA's decision acknowledges that these products contain lower levels of harmful constituents compared to other smokeless tobacco options. The authorization covers several Swedish Match USA products, including 9-milligram Zyn Ultra pouches in various flavors, offering consumers more choices in strength and taste.

This development follows an earlier FDA decision in June that permitted 20 Zyn variants to be marketed as less harmful than traditional cigarettes. Together, these approvals expand the number of Zyn products with U.S. regulatory backing, supporting Philip Morris's strategic growth in the nicotine pouch sector, which is currently the fastest-growing nicotine category nationwide.